Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Transcutaneous Vagal Nerve Stimulation in Treatment-Resistant Depression: A Feasibility Study

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Sudden unexpected death in epilepsy in persons younger than 50 years: A retrospective nationwide cohort study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transcutaneous Vagus Nerve Stimulation in Patients With Severe Traumatic Brain Injury: A Feasibility Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Anfaldsfænomener

    Research output: Chapter in Book/Report/Conference proceedingBook chapterEducation

  4. Epilepsi, synkope og søvnforstyrrelser

    Research output: Chapter in Book/Report/Conference proceedingBook chapterEducation

  • Kristin Evensen
  • Martin Balslev Jørgensen
  • Anne Sabers
  • Klaus Martiny
View graph of relations

BACKGROUND: Major depression (MD) contributes significantly to the global burden of disease with up to one-third of patients being treatment resistant. Therefore, the development of new treatment options for treatment-resistant depression (TRD) is needed. Vagus nerve stimulation (VNS) has shown mood improvements in patients with TRD. However, due to high costs related to the implantation and the invasive nature of VNS, an application with transcutaneous VNS (t-VNS) has been developed stimulating a vagal nerve branch in the earlobe (Arnold's nerve). A few studies with t-VNS in MD has shown a possible antidepressant effect, but feasibility is poorly described and patients with TRD have not been investigated.

OBJECTIVES: As the full antidepressant effect of t-VNS takes months we wanted to assess feasibility and side effects of daily treatments.

MATERIALS AND METHODS: Single-arm feasibility trial assessing compliance, usability, side effects, cognitive speed, and depression in a four-week period with a recommended t-VNS stimulation duration of four hours per day in patients with TRD. The primary outcome was compliance with 80% of the recommended daily treatment time.

RESULTS: Compliance threshold was reached for 80.0% of the 20 included participants. Usability was acceptable. Side effects were few, mild or moderate, mostly as local effects at the contact point in the ear. The device was difficult to use for some participants. A statistically significant reduction in depression severity and an increase in cognitive speed were seen with unchanged suicidal ideation and sleep.

CONCLUSIONS: We would recommend larger long-term randomized studies of t-VNS to access any antidepressant effect in TRD. The design of the device might be improved for higher usability.

Original languageEnglish
Publication statusE-pub ahead of print - 4 Feb 2021

    Research areas

  • Psychiatric somatic therapies, treatment-resistant depression, vagus nerve stimulation

ID: 64186052